Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor
- PMID: 23430345
- DOI: 10.1007/s11523-013-0267-8
Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor
Similar articles
-
Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial.Clin Cancer Res. 2015 Jan 1;21(1):49-59. doi: 10.1158/1078-0432.CCR-14-0940. Epub 2014 Oct 15. Clin Cancer Res. 2015. PMID: 25320355 Free PMC article. Clinical Trial.
-
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.Breast Cancer Res Treat. 2011 Jan;125(2):447-55. doi: 10.1007/s10549-010-1260-x. Epub 2010 Nov 25. Breast Cancer Res Treat. 2011. PMID: 21107682 Clinical Trial.
-
Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.Clin Cancer Res. 2011 Feb 15;17(4):871-9. doi: 10.1158/1078-0432.CCR-10-2621. Epub 2010 Dec 22. Clin Cancer Res. 2011. PMID: 21177764 Clinical Trial.
-
Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.Expert Rev Clin Pharmacol. 2013 Sep;6(5):465-82. doi: 10.1586/17512433.2013.827397. Epub 2013 Aug 23. Expert Rev Clin Pharmacol. 2013. PMID: 23971829 Review.
-
Everolimus: a new hope for patients with breast cancer.Curr Med Res Opin. 2014 Jan;30(1):75-87. doi: 10.1185/03007995.2013.846253. Epub 2013 Oct 14. Curr Med Res Opin. 2014. PMID: 24050600 Review.
Cited by
-
Surgical Treatment of Sacroiliac Pigment Villous Nodular Synovitis: A Case Report and Literature Review.Front Surg. 2022 Apr 28;9:760704. doi: 10.3389/fsurg.2022.760704. eCollection 2022. Front Surg. 2022. PMID: 35574542 Free PMC article.
-
Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour.Anticancer Drugs. 2020 Jan;31(1):80-84. doi: 10.1097/CAD.0000000000000844. Anticancer Drugs. 2020. PMID: 31567307 Free PMC article.
-
mTOR inhibitors in urinary bladder cancer.Tumour Biol. 2016 Sep;37(9):11541-11551. doi: 10.1007/s13277-016-5083-1. Epub 2016 May 27. Tumour Biol. 2016. PMID: 27235118 Review.
-
Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.Curr Treat Options Oncol. 2016 Feb;17(2):10. doi: 10.1007/s11864-015-0385-x. Curr Treat Options Oncol. 2016. PMID: 26820289 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
